Articles

Moffitt Cancer Center study findings show risk is greater among unmarried men and men who smoke.

Study by Johns Hopkins researchers may affect future treatment plans for African American men diagnosed with very low-risk prostate cancer.

Study shows medical insurance coverage may influence the growing number of papillary thyroid cancer diagnoses.

New study shows that more than 6% of patients diagnosed with melanoma experience a recurrence a decade or more following initial treatments.

Study shows higher mortality rates among survivors of heart failure diagnosed with cancer.

This article discusses ongoing clinical investigations of the agent in a wide range of therapeutic areas.

Bendamustine is currently approved for the treatment of chronic lymphocytic leukemia (CLL), and many ongoing studies are investigating its efficacy in drug combinations.

Bendamustine has demonstrated activity as monotherapy and in combination for patients with lymphoid and hematologic as well as solid tumors.

At the 54th Annual Meeting of the American Society of Hematology, a number of abstracts were presented demonstrating the efficacy and toxicities of bendamustine either alone or in combination with other agents for the treatment of several lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and indolent as well as aggressive non-Hodgkin lymphoma (NHL).

Scientists at Baylor Research Institute have created a simple blood test that aids in the detection of colorectal cancer.